UNSPSC 51343823: Darunavir/Cobicistat

Darunavir is a protease inhibitor co-formulated with the cobicistat booster that has been shown to be effective under ART for the treatment of HIV.

UNSPSC 51343823 Darunavir/Cobicistat, a Commodity code, appears in state and local procurement records with minimal recent activity directly aligned to this specific antiretroviral pharmaceutical product. The code nominally covers individual active pharmaceutical ingredients used in HIV treatment; however, the recent opportunities block contains no solicitations for Darunavir/Cobicistat itself. State and local health departments, counties, and municipal health agencies typically procure antiretroviral drugs and related pharmaceutical supplies through cooperative purchasing agreements, group purchasing organizations (GPOs), and master service agreements with pharmaceutical wholesalers rather than through discrete RFP or IFB notices for individual drug compounds. When HIV treatment pharmaceuticals appear in state and local procurement activity, they are often bundled within broader generic multi-source pharmaceutical contracts, clinical pharmacy services agreements, or public health agency medication supply contracts.

The recent opportunities associated with this code do not support a meaningful market characterization or geographic concentration. One opportunity—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic multi-source pharmaceuticals and OTC products RFP (S1070000015802), posted January 20, 2026, with responses due March 26, 2026—addresses pharmaceutical supply contracting at scale across multiple state and local members, but targets generic and OTC products rather than branded antiretrovirals like Darunavir/Cobicistat. No recent competitive solicitations naming this specific drug, issuing body, or response date appear in the block. Vendors pursuing this code should monitor cooperative purchasing vehicles, state Medicaid pharmacy services solicitations, and public health agency clinical supply contracts rather than expect discrete opportunities for individual antiretroviral compounds.